 BOCA RATON, Fla., Aug. 10, 2021 GLOBE NEWSWIRE -- AzurRx BioPharma, Inc. AzurRx or the Company NASDAQ: AZRX, a company specializing in the development of targeted non-systemic, recombinant therapies for gastrointestinal GI diseases, today announced the completion of site initiation visits and the addition of five 5 new clinical trial sites in Ukraine for the ongoing RESERVOIR Phase 2 clinical trial evaluating FW-1022 as a treatment for COVID-19-related gastrointestinal GI infections. FW-1022 is a proprietary oral tablet formulation of micronized niclosamide developed for the treatment of COVID-19-related GI infections. 